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Abstract
Background: Proximal femoral fractures are associated with increased morbidity and mortality. Pre-existing
malnutrition and weight loss amongst this patient group is of primary concern, with conventional nutrition support
being largely ineffective. The inflammatory response post proximal femoral fracture surgery and the subsequent
risk of cachexia may explain the inability of conventional high energy high protein management to produce an
anabolic response amongst these patients. Omega-3 fatty acids derived from fish oils have been extensively
studied for their anti-inflammatory benefits. Due to their anti-inflammatory properties, the benefit of fish oil
combined with individualized nutrition support amongst proximal femoral fracture patients post surgery is an
attractive potential therapeutic strategy. The aim of the ATLANTIC trial is to assess the potential benefits of an anti-
inflammatory dose of fish oil within the context of a 12 week individualised nutrition program, commencing seven
days post proximal femoral fracture surgery.
Methods/Design: This randomized controlled, double blinded trial, will recruit 150 community dwelling elderly
patients aged ≥65 years, within seven days of surgery for proximal femoral fracture. Participants will be randomly
allocated to receive either a 12 week individualized nutrition support program complemented with 20 ml/day anti-
inflammatory dose fish oil (~3.6 g eicosapentaenoic acid, ~2.4 g docosahexanoic acid; intervention), or, a 12 week
individualized nutrition support program complemented with 20 ml/day low dose fish oil (~0.36 g
eicosapentaenoic acid, ~0.24 g docosahexanoic acid; control).
Discussion: The ATLANTIC trial is the first of its kind to provide fish oil combined with individualized nutrition
therapy as an intervention to address the inflammatory response experienced post proximal femoral fracture
surgery amongst elderly patients. The final outcomes of this trial will assist clinicians in the development of
effective and alternative treatment methods post proximal femoral fracture surgery which may ultimately result in a
reduction in systemic inflammation, loss of weight and lean muscle and improvements in nutritional status,
mobility, independence and quality of life among elderly patients.
Trial Registration: ACTRN12609000241235
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Osteoporotic fractures and injurious accidental falls are
associated with increased morbidity and mortality in
older adults [1-4]. Proximal femoral fractures (PFF) are
among the most common causes for acute admission to
orthopaedic wards with a 30% mortality rate 12-months
post surgery [3]. Moreover, less than 50% of patients
return to pre-fracture levels of mobility and indepen-
dence, with older adults who survive a hip fracture
being three times more likely to be functionally depen-
dent, 50% requiring long-term assistance with routine
functional activities and up to 25% requiring full-time
residential care [5-7].
Malnutrition in the elderly is commonly overlooked in
a clinical setting [8,9]. There is an extremely high preva-
lence (up to 63%) of pre-existing malnutrition amongst
PFF patients on acute admission to hospital [9,10]. Mal-
nutrition in this setting has consistently been demon-
s t r a t e dt ol e a dt oa d v e r s ep a t i e n to u t c o m e st h r o u g h
increasing the risk of postoperative complications [11],
limiting participation in rehabilitation and delaying opti-
mal recovery of ambulatory status and independence
[12,13]. Moreover, there is a marked decline in nutri-
tional status in these patients throughout the acute
admission, commencing within one week of admission
and continuing for six to twelve weeks post surgery
[14,15].
Conventional nutritional management of PFF patients
involves the provision of high energy, high protein diets,
however the evidence for this approach is largely uncon-
vincing. A systematic review of the literature highlighted
that most nutrition support provided for PFF patients is
based on the provision of a standard volume of high
caloric oral supplement rather than individualised diet-
ary requirements [16]. One of the primary limitations of
as t a n d a r da p p r o a c hi st h ef a i l u r et ob ep a t i e n to r i e n -
tated and tailor dietary therapy to each individual’s
energy and protein deficits associated with pre-existing
malnutrition and inadequate dietary intakes post PFF
surgery [16].
Weight loss in older adults, particularly loss of lean
muscle, is highly predictive of increased morbidity and
mortality [17-19]. Furthermore, rapid deconditioning of
muscle may be responsible for secondary hospital read-
missions, repeat injurious falls and loss of independence
in older adults [20,21]. Cachexia, characterized by dis-
proportionate muscle wasting, associated with systemic
inflammation and elevated plasma cytokines [17], is a
plausible explanation for the inability of conventional
nutrition support programs to generate an anabolic
response in PFF patients. It is critical, therefore, that
caloric and protein supplementation is supported with
other aggressive treatment strategies in the treatment of
cachexia [22,23].
As a biomarker of cachexia, the magnitude of the
inflammatory response post PFF surgery, and interven-
tions to reduce this response, has not been adequately
investigated. The normal physiological response to a
major insult, such as the trauma of PFF and the subse-
quent surgical repair, is characterized by the activation
of the hypothalamic pituitary adrenal axis and sympa-
thetic nervous system with simultaneous activation of
the immune system and systemic inflammation [24].
Persistent inflammation among patients recovering from
PFF is recognized as a major contributing factor to poor
patient outcomes post surgery [25]. Specifically, the
combination of stress hormones and pro-inflammatory
cytokines promotes catabolism and malnutrition, and
impairs normal gastrointestinal functioning such that
macronutrient utilization may be compromised [26].
Moreover, inflammation in this population group is pre-
dictive of a decrease in physical functioning, the onset
of disability and mortality [27-30].
Due to their anti-inflammatory properties and poten-
tial to suppress the metabolic consequences of PFF, fish
oils are a relatively simple and promising therapeutic
strategy for the treatment of cachexia in this population
group. Provision of adequate fish oil in conjunction with
adequate energy and protein could theoretically improve
outcomes for PFF patients. Fish oils, more specifically
eicosapentaenoic (EPA) and docosahexanoic (DHA)
acids, have been extensively studied for their anti-
inflammatory properties in inflammatory conditions
including rheumatoid arthritis [31] and cardiovascular
disease [32]. However, the novel therapeutic benefit of
fish oils in patients with end-stage disease is also attract-
ing wider attention with research suggesting that fish
oils may ameliorate cachexia in patients with advanced
cancer [33]. One proposed mechanism of the anti-
inflammatory action of fisho i l si si m p a i r m e n to ft h e
release of acute phase proteins and pro-inflammatory
cytokines, in particular C-reactive protein (CRP), inter-
leukin-6 (IL-6), tumor necrosis factor-∝ (TNF-∝)a n d
interleukin-1 (IL-1) [34].
The aim of the present randomised controlled trial
(RCT) is to implement a 12 week, individualised nutri-
tion program complemented with an anti-inflammatory
dose of fish oil (20 ml/day containing 3.6 g EPA and 2.4
g DHA), commencing 7 days post PFF surgery that will
result in clinically important and statistically significant
improvements in terms of quality of life, appetite, body
composition and physical function. Comparisons will be
drawn with a control group receiving 10% of the active
fish oil dose.
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Design overview
This is a double blinded randomized controlled trial of
150 adults aged ≥65 years, recruited within seven days
of surgery for PFF and followed post discharge for up to
12 months. Participants identified with cachexia will be
randomly allocated to receive either a 12 week indivi-
dualized nutrition program complemented with an anti-
inflammatory dose of fish oil (20 ml/day providing ~3.6
g EPA and ~2.4 g DHA per day) (intervention),o r ,a
12 week individualized nutrition program complemented
with 20 ml/day low dose fish oil (~0.36 g EPA, ~0.24 g
DHA) (control). An overview of the recruitment
method, randomisation process and follow-up proce-
d u r e si sp r o v i d e di nF i g u r e1 .T h i st r i a lh a sb e e n
approved by the Human Research and Ethics Commit-
tee (HREC) at the Royal Adelaide, Flinders Medical
Centre and Flinders Private Hospitals, and registered
with the Australian and New Zealand Clinical Trials
Registry (reg no: ACTRN12609000241235).
Recruitment and Eligibility
Participants will be consecutively recruited from admis-
sions to the acute orthopaedic wards at Flinders Medical
Centre, Flinders Private Hospital and the Royal Adelaide
Hospital, Adelaide, South Australia. Project personnel,
in consultation with members of the orthogeriatric
team, will screen all orthopaedic patients against eligibil-
ity criteria, outlined in Table 1. All participants will be
recruited within 7 days of PFF surgery, with the inter-
vention to commence on day 7 post surgery for repair
of PFF.
Medical records will be audited to confirm age, suburb
of residence and details of injury. A complete medication
history, relevant biochemical analyses, information on
risk factors for haemorrhagic stroke or increased bleeding
times, and co-morbidities likely to reduce life expectancy
to <12 weeks will be collected from each participant
prior to recruitment. With exception to low-dose aspirin
and prophylactic doses of low molecular weight (LMW)
heparin, patients receiving treatment doses of any antith-
rombotic agent, including those taking anti-platelet func-
tioning drugs, will not be eligible to participate in the
study. To identify preliminary evidence of cachexia,
patient serum CRP levels >6 mg/L will be used as the
standard in screening prospective participants.
A validated fish food frequency questionnaire (FFQ)
[35] will be administered for the purposes of estimating
current intake of n-3 fatty acids. Participants with a
daily intake of >2 g total n-3 fatty acids as per FFQ will
be deemed ineligible to participate in the present study.
Any seafood allergy documented in patient medical
records will be noted but confirmed with the patient
and family if the patient is otherwise eligible.
Risk of subsequent weight loss will be assessed in the
recruitment of participants using the validated Simpli-
fied Nutrition Appetite Questionnaire (SNAQ), a four
item questionnaire derived from the eight item Council
on Nutrition Appetite Questionnaire [36]. SNAQ inves-
tigates appetite, satiety following meals, food taste and
usual meal frequency. Responses are scored on a five-
point scale with a score <14/20 representing a signifi-
cant risk of weight loss. Participants who are deemed
not at risk of significant weight loss (i.e. score ≥14/20
weight) will be ineligible for the present study.
The Mini Mental State Examination (MMSE) [37] will
be administered to assess cognitive impairment and
those who achieve <18/30 will be excluded due to their
inability to independently follow therapeutic advice and
difficulty in verification of self-reported outcomes.
When assessing MMSE, any patient who does not score
≥18/30 on the first attempt post surgery, but is sus-
pected of experiencing post-operative delirium, will be
reassessed at a later date (within 7 days of surgery) in
order to maximise the opportunity of achieving a score
≥18/30. For prospective participants who score between
18 and 24/30, consent will also be obtained from next
of kin to confirm participation.
All patients who meet the eligibility criteria will be
invited to participate in this trial. Project personnel will
provide potential participants with a detailed description
of the study and the procedures to be performed. If
research personnel are satisfied that the potential parti-
cipant completely comprehends the information and the
implications of their involvement in the study, written
informed consent will be obtained prior to commence-
ment of baseline measures and randomisation. If study
personnel have any doubts that a participant has the
capacity to give informed consent, third party consent
will be obtained from a relative or immediate caregiver.
Measurements and Procedures
Project personnel will assess the selected outcome mea-
sures (outlined below) at baseline, 6 weeks and 12 weeks
with selected measures at 12 months. Project personnel
will remain masked to treatment allocation for the assess-
ment of all outcome measures. A telephone follow-up will
be performed at 12-months to collect information on
quality of life, physical autonomy, changes in level of
accommodation and mortality. Outcome measures have
been selected based on their suitability for older adults fol-
lowing PFF surgery, strength of the evidence to support
validity and reliability, and significance to rehabilitation.
All outcome assessments will be conducted in a clinic set-
ting. For all participants who have been discharged post
PFF surgery, transportation will be provided by project
personnel. It is anticipated that outcome assessments will
take approximately 90 minutes in duration.
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Lean body mass and bone mineral density (baseline,
6 and 12 weeks) Lean body mass and bone mineral
density will be measured using Dual Energy X-ray
Absorptiometry (DEXA: Lunar Prodigy Pro, GE Health-
care, UK). Loss of lean body mass is a key feature in the
development of cachexia therefore assessment of the
effect of fish oil on body composition is important.
Figure 1 Study design and assessment points. Abbreviations: PFF - proximal femoral fracture; EPA - eicosapentaenoic acid; DHA -
docosahexanoic acid; DEXA - dual energy x-ray absorpitometry; REE - resting energy expenditure; MNA - mini nutritional assessment; ADL -
activities of daily living; AQoL - assessment of quality of life instrument.
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hip) will also be examined.
P e r c e n tw e i g h tc h a n g e( b a s e l i n e ,6a n d1 2w e e k s )
Weight change is a key feature in the monitoring of
recovery from cachexia. Body weight will be measured to
the nearest 0.1 kg following an overnight fast, using cali-
brated electronic digital scales (Tanita, BF-679W, Illinois,
United States) with patients in light clothing and without
footwear. Alternatively, for inpatients at baseline, a cali-
brated weigh chair will be used. Percent weight change
will be determined by calculating the difference from
baseline weight, divided by baseline weight, multiplied by
100. Research Dietitians visiting participants fortnightly
will also weigh participants routinely as a means of moni-
toring patient progress and nutritional status.
Nutritional status (baseline, 6 and 12 weeks) The
Mini Nutritional Assessment (MNA), a validated nutri-
tion screening and assessment tool, will be used to clas-
sify patients as well-nourished, at risk of malnutrition or
malnourished [38]. This assessment collects information
from four main domains: anthropometric measures
(body mass index (BMI) and self reported weight loss),
global assessment (lifestyle, medications and mobility),
dietary assessment (energy and protein intake and num-
ber of meals), and subjective assessment (self-rated
health and nutritional status).
Triceps skinfold thickness will be assessed using cali-
brated skinfold calipers (Harpenden calipers, Baty Inter-
national, Sussex, United Kingdom) and combined with
mid-arm circumference to determine corrected arm
muscle area (CAMA) and thereby estimate skeletal mus-
cle mass [37].
Resting energy expenditure (baseline, 6 and 12 weeks)
Resting energy expenditure (REE) will be measured
using a hand held portable indirect calorimeter (Med-
Gem, Health-Tech, Germany). REE will be assessed fol-
lowing a fasting period of at least 4 hours. While sitting
in a relaxed and upright position, participants will be
required to breathe normally into a disposable “scuba-
type” mouthpiece where oxygen consumption will be
measured until steady state breathing is detected.
Physical function
Physical autonomy (baseline, 6 and 12 weeks) The
ability to participate in activities of daily living (ADL)
will be assessed using a validated instrumental and phy-
sical ADL tool [39]. The instrumental ADL assesses the
ability to shop, prepare meals, conduct housework
duties, wash clothing, use the telephone, manage
finances and take medications, whereas the physical
ADL tool assesses the ability to eat, dress, shower, get
into and out of bed, maintain self-appearance and walk.
Physical autonomy is considered an important require-
ment of independent living, where poor performance is
an established risk factor for morbidity and mortality
amongst older adults [39,40].
Chair stand test (baseline and 12 weeks) This assess-
ment correlates with lower limb muscle strength, which
is an integral component of physical independence
amongst the elderly population [41]. Participants will be
assessed using a validated physical performance test [42]
Table 1 Eligibility criteria for ATLANTIC trial
Inclusion criteria Exclusion criteria
Aged ≥65 years Severe cognitive impairment (MMSE <18/30)
PFF confirmed by radiology report PFF not fall-related, is pathological or is peri-prosthetic
Undergone surgery for fixation of hip fracture Initiation of anti-inflammatory drugs or corticosteroids within the previous two weeks
Reside within existing local service boundaries Ingestion of ≥2 g total omega-3 daily as per fish FFQ
Preliminary evidence of cachexia (CRP ≥6 mg/L) Seafood allergy
At risk of significant weight loss (SNAQ score <14/20) Life expectancy <12 weeks
Inability to communicate effectively due to
■ Blindness
■ Deafness
■ Lack of a translator
Inability to provide informed consent
Diagnosed with one of the following haemorrhagic stroke risk factors Unstable hypertension
■ Atrial fibrillation
■ Inherited disorders - polycystic kidney disease, Ehlers-Danlos syndrome type IV,
neurofibromatosis type I, Marfan syndrome, moyamoya disease
Diagnosed with a bleeding disorder such as the following:
■ von Willebrand disease
■ Haemophilia
Receiving treatment doses of any antithrombotic agent
Those on dual anti-platelet function drugs or any anti-platelet drugs with exception
of low dose aspirin.
Abbreviations: MMSE - Mini Mental State Examination; PFF - proximal femoral fracture; FFQ - food frequency questionnaire; CRP - C-reactive protein.
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five repetitions of rising from a seated position and sub-
sequently returning to their original seated position as
quickly as possible. The standard protocol has been
amended slightly to account for suitability within this
patient group. Specifically, participants will be asked to
perform the test on two separate occasions, once with
the use of arms (i.e. using arm rests to push off chair)
and secondly, as per protocol, without the use of arms
(i.e. with arms folded across chest).
Laboratory assessment
Biochemical markers of inflammation (baseline, 6
and 12 weeks) Fasting blood samples will be collected
b yat r a i n e dr e s e a r c hn u r s ea te a c ho ft h eo u t c o m e
assessments. Serum samples will be obtained, processed
and stored frozen at -70°C. When stored at such tem-
peratures, there is evidence to suggest inflammatory
cytokines such as IL-6 remain stable in serum for many
years [43]. The analyses of inflammatory markers
including CRP, TNF-∝,I L - 1 b, IL-6 will be assayed using
commercial cytokine enzyme-linked immunosorbent
high-sensitivity kits.
Adherence to the fish oil intervention (baseline, 6 and
12 weeks) Whole blood samples will be collected and
processed allowing for the separation of plasma from
red blood cells. Fatty acids will subsequently be
extracted from the erythrocyte phospholipid membrane
and analysed to evaluate adherence to the fish oil
intervention.
Additionally, study participants will be required to
maintain a diary outlining their consumption of fish oil,
which will then be monitored by the research Dietitian
at fortnightly visits; any remaining fish oil will be mea-
sured to monitor participant adherence.
Other assessments
Quality of life (baseline, 6 and 12 weeks; 12 month
follow-up) Health-related quality of life will be assessed
using the Assessment of Quality of Life Instrument
(AQoL) [44], a 15 item survey with high internal consis-
tency covering five domains: illness, independent living,
social relationships, physical senses and psychological
well-being. The resultant summary score can be trans-
formed into a utility index, and subsequently, quality-
adjusted life years calculated.
Frailty index (baseline, 6 and 12 weeks) Frailty will be
assessed using the Edmonton Frailty Index [45] a valid
and reliable survey that can be used routinely by non-
geriatricians, covering nine domains: cognition, general
health status, social support, functional independence,
nutrition, medication use, mood, continence, and func-
tional performance.
Monitoring adverse effects to fish oil
Gastrointestinal side effects Any gastrointestinal side
effects of the fish-oil, although unlikely at the proposed
dose, will be self-reported by participants at fortnightly
visits, and include the monitoring of gastrointestinal
symptoms such as nausea, vomiting, diarrhoea, abdom-
inal pain and steatorrhoea. If participants are unable to
tolerate the proposed dose, fish oil capsules will be
offered at the equivalent dose. Alternatively the dose
will be progressively reduced until any side effects have
been resolved.
Interactions with medications Prophylactic use of
LMW heparin or low-dose aspirin will be carefully mon-
itored by research personnel at baseline and throughout
fortnightly visits. If any adverse events are observed,
such as frequent bruising or increased bleeding time,
these will be documented and reviewed by the trial
safety management board and further reported to the
human research ethics committee. If prophylactic doses
for any anticoagulant medication increases to a treat-
ment dose, the administration of fish oil will cease
immediately. However, in a previous clinical trial of car-
diac patients who were taking an anti-inflammatory
dose of fish oil, in addition to aspirin and Warfarin ther-
apy, no increase in bleeding episodes were observed
[46]. Although the potential interaction between fish oil
and antithrombotic agents among elderly cachectic
patients has not been adequately examined, as a precau-
tionary measure, patients taking treatment doses of
anticoagulants are excluded from the present study
Randomisation and Blinding
Participants will be randomly assigned to either an
intervention or control group following the completion
of all baseline measurements. Allocation to groups will
be managed by the Flinders University statistician who
provides a randomisation service using computerised
randomisation software. Allocation will be stratified by
hospital admission site due to the likely difference in
services provided across the public and private settings.
Allocation will also be stratified by fish intake (>2 oily
fish meals/week; ≤ 2 oily fish meals/week) as determined
by the validated fish FFQ [35]. This is a double-blinded
controlled trial with all research personnel to remain
masked to the treatment allocation of participants.
Intervention
Individualised nutrition care plan
All participants, independent of group allocation, will
receive a 12 week well-integrated, coordinated, indivi-
dualised nutrition care plan in addition to a daily dose
of either an anti-inflammatory dose or low dose of fish
oil. The provision of the nutrition care plan is designed
to ensure that both groups receive best available nutri-
tion care for the prevention of starvation-related muscle
wasting and hence will allow the study to evaluate
whether an anti-inflammatory dose of fish oil improves
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alone.
The research Dietitian will perform a comprehensive
nutritional assessment upon each participant’s entry into
the study as a basis for developing a nutrition care plan
consistent with estimated nutritional requirements and
nutritional rehabilitation goals. As a basis for developing
a nutrition program that will achieve positive energy
balance, and therefore prevent clinically significant
weight loss, REE of each participant will be measured. A
factorial method, accounting for injury and weight gain
factors, will be used to estimate the total energy expen-
diture for each participant. Nutrient Reference Values
[47] will be used as a basis for determining macronutri-
ent and micronutrient requirements.
To assess dietary intake, the research Dietitian will
perform a standardised dietary interview (3-pass 24-
hour recall) with each participant to determine total
energy and nutrient intake. Strategies for achieving
energy and nutrient requirements will include dietary
counselling with attention to timing, size and frequency
of meals, recommendations for nutrient dense foods,
provision of recipes and referral to community meal
programs and providers. Supplementation with commer-
cial high-energy, high-protein supplements as well as
multi-vitamins will also be considered to achieve opti-
mal nutritional status.
Fish oil supplementation
For maximum adherence and minimal cost, administration
of EPA and DHA will occur via unencapsulated fish oil
taken on fruit juice or vegetable juice. Participants will be
required to float 20 ml fish oil (Melrose Omega 18/12 -
Aust L93186; Melrose Health, Victoria, Australia) on 30-40
ml juice, or any other flavoured, non-fizzy drink. The fish
oil concentrate is flavoured with lemon and lime to mask
the fish scent and taste. To avoid any potential side effects
associated with the consumption of fish oil, participants
are asked to consume the fish oil on juice with breakfast to
avoid consumption on an empty stomach. If this dosage is
not tolerated, the frequency and volume may be adjusted
in conjunction with the research Dietitian, or alternatively
fish oil capsules will be offered as an alternative to provide
similar concentrations of EPA and DHA as the liquid oil (a
total of 17 capsules per day, Melrose - Omega, Aust
L156237; Melrose Health, Victoria, Australia).
The anti-inflammatory dose of fish oil selected for the
intervention group provides ~3.6 g EPA and ~2.4 g
DHA per 20 ml. The low-dose fish oil selected for the
control group will be prepared to contain 10% of the
active dose, which is also flavoured with lemon and lime
to assist in maintaining participant blinding (~0.36 g
EPA and ~0.24 g DHA per 20 ml). As with the interven-
tion group, those participants in the control group who
refuse to continue with the allocated dose of liquid oil
will be offered fish oil capsules providing the equivalent
dosage of EPA and DHA.
As an inpatient, at baseline, the participant’s fish oil
will be dispensed by each hospital’s pharmacy and admi-
nistered on the inpatient medication round. The phar-
macy will also dispense outpatient supplies alongside
other discharge medications.
Fortnightly visits
The research Dietitian will perform fortnightly home
visits to all participants (intervention and control) over
12 weeks to perform dietetic care and maximise partici-
pant nutritional status by way of reviewing the nutrition
care plan, dietary counselling and education, monitoring
participant weight, ensuring energy and nutrient
requirements are achieved as well as monitoring poten-
tial gastrointestinal side effects from the dose of fish oil.
Sample Size Considerations
Quality of life is the primary outcome in this study and
was selected because quality of life is an important deter-
minant of future outcomes. It is recommended that half
the baseline standard deviation of raw scores provides an
appropriate estimate of the minimally clinically important
difference for quality of life, and this form of estimation is
useful in the absence of direct measurements of important
change [48]. Using this method, the minimally clinically
important difference was calculated to be approximately 2
points for the AQoL. A sample size of 64 participants per
group is expected to achieve this difference between the
two groups (power 80%, alpha = 0.05). To allow for deaths
and withdrawals (5% and 10% respectively), 150 partici-
pants will be recruited (75 per group). This sample size
will provide 92% power to detect a difference of 3 (effect
size of 0.6) on the appetite questionnaire.
Statistical Analysis
All statistical analyses will be performed using SPSS for
Windows, version 18 (SPSS Inc, Chicago, USA). Data
will be entered into a centralised secure database with
remote web access (CareSearch Research Data Manage-
ment System - http://www.caresearch.com.au) and will
subsequently be exported into SPSS software for ana-
lyses. Primary analysis for this study will be undertaken
using intention to treat principles. Independent samples
t-tests, Mann-Whitney U test and Chi-square test of
association will be used as appropriate to compare
groups at baseline. To determine differences between
the groups at the primary end-point (12 weeks),
ANCOVA or logistic regression will be used with mod-
els adjusted according to potential confounders.
Time Frame
This study has a 3.5-year time frame. It is expected that
recruitment will commence late 2010 and continue until
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required to finalise data collection and six months to
complete data analysis and prepare manuscripts for sub-
mission to peer reviewed scientific journals.
Discussion
To the best of our knowledge, the ATLANTIC trial is
the first of its kind to provide fish oil and individualised
nutrition therapy as an intervention to address the dete-
rioration in nutritional status which commonly occurs
in PFF patients. This trial will explore more detailed
information about the key markers of cachexia than pre-
vious work in this population group, particularly con-
cerning the magnitude of inflammation experienced
post PFF.
This trial will commence earlier than previous
research where fish oil has been explored in the treat-
ment of cancer cachexia. Given that the natural process
of bone healing is influenced by a variety of systemic
and local factors, including an early inflammatory phase
[49], the intervention will commence day 7 following
PFF surgery with an ongoing intervention phase of 12
weeks. The use of anti-inflammatory medication
throughout the first week of bone healing may alter this
natural inflammatory process and potentially inhibit
normal bone healing [49]. Furthermore, the literature
provides convincing evidence that markers of cachexia,
including poor appetite [8,50], involuntary weight loss,
in particular lean muscle [51,52], increased REE [53-55]
and decreased albumin [55,56] are commonly observed
in patients recovering from PFF.
Evidence exploring the inflammatory response post
PFF surgery in this population group is scant. Previous
research using fish oil as an intervention for cachexia
has used the model of pancreatic cancer, however there
have been considerable limitations in this research
including heterogeneous samples representing mixed
tumour types and severity, the use of variable and lar-
gely insufficient doses of EPA, and in some cases, the
administration of fish oil for short durations [57].
Furthermore, the likelihood of demonstrating an effect
with fish oil for patients recovering from PFF surgery is
likely to be more favourable than patients with advanced
cancer given the more acute nature of the injury. With
evidence now suggesting a persistent inflammatory
response in patients post PFF surgery, and that conven-
tional nutrition support alone is unconvincing, in an
attempt to dampen the inflammatory response, it is a
logical extension to evaluate whether patients recovering
from PFF surgery respond positively to fish oil as an
intervention in concurrence with individualized nutri-
tion support.
It is rare that PFF patients receive any significant
level of nutrition support as part of standard care
following their acute care admission. A major strength
of the ATLANTIC trial is that it takes a comprehen-
sive approach to nutrition management where all par-
ticipants receive individual dietary counselling and
nutrition education from an Accredited Practicing
Dietitian. This includes the provision of dietary educa-
tion and counselling in the way of dietary modifica-
tions, food fortification and oral supplementation to
ensure individual energy, protein and other nutrient
requirements are achieved. This is particularly critical
given the lack of evidence that oral supplementation
alone is effective at improving clinical outcomes in
this patient group [16].
To minimize the devastating consequences of cachexia
as well as secondary hospital admissions, it is critical
that adequate rehabilitation and nutrition support ser-
vices post PFF surgery are provided. The results of this
trial will assist clinicians in the development of more
effective and alternative treatment methods, such as an
anti-inflammatory dose of fish oil post PFF surgery
which may ultimately result in a reduction in systemic
inflammation, weight loss, particularly muscle mass,
improvements in nutritional status, mobility, indepen-
dence and quality of life among these patients.
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